Clinical trial
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
NCT00226915 · Japanese Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00226915 |
|---|---|
| Title | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma |
| Official title | Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma |
| Lead sponsor | Japanese Gynecologic Oncology Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel+Carboplatin |
| Enrollment | 637 |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Sep 27, 2005 |
| Last update posted | Feb 17, 2020 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: